

# Vanessa Smith

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/608615/publications.pdf>

Version: 2024-02-01

224  
papers

8,132  
citations

61984

43  
h-index

60623

81  
g-index

225  
all docs

225  
docs citations

225  
times ranked

5775  
citing authors

#	ARTICLE	IF	CITATIONS
1	Update of EULAR recommendations for the treatment of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1327-1339.	0.9	794
2	Mapping and predicting mortality from systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1897-1905.	0.9	410
3	Proteome-wide Analysis and CXCL4 as a Biomarker in Systemic Sclerosis. <i>New England Journal of Medicine</i> , 2014, 370, 433-443.	27.0	365
4	Standardisation of nailfold capillaroscopy for the assessment of patients with Raynaud's phenomenon and systemic sclerosis. <i>Autoimmunity Reviews</i> , 2020, 19, 102458.	5.8	231
5	Assessing microvascular changes in systemic sclerosis diagnosis and management. <i>Nature Reviews Rheumatology</i> , 2010, 6, 578-587.	8.0	205
6	Macrophage M1/M2 polarization and rheumatoid arthritis: A systematic review. <i>Autoimmunity Reviews</i> , 2019, 18, 102397.	5.8	203
7	Identification of Novel Genetic Markers Associated with Clinical Phenotypes of Systemic Sclerosis through a Genome-Wide Association Strategy. <i>PLoS Genetics</i> , 2011, 7, e1002178.	3.5	201
8	Pathophysiology of systemic sclerosis: current understanding and new insights. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 753-764.	3.0	200
9	How to perform and interpret capillaroscopy. <i>Best Practice and Research in Clinical Rheumatology</i> , 2013, 27, 237-248.	3.3	163
10	A circulating cell population showing both M1 and M2 monocyte/macrophage surface markers characterizes systemic sclerosis patients with lung involvement. <i>Respiratory Research</i> , 2018, 19, 186.	3.6	149
11	Do worsening scleroderma capillaroscopic patterns predict future severe organ involvement? a pilot study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1636-1639.	0.9	146
12	Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 979-987.	0.9	142
13	Nailfold Capillaroscopy for Prediction of Novel Future Severe Organ Involvement in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2013, 40, 2023-2028.	2.0	137
14	Predictors of progression in systemic sclerosis patients with interstitial lung disease. <i>European Respiratory Journal</i> , 2020, 55, 1902026.	6.7	134
15	Reliability of the qualitative and semiquantitative nailfold videocapillaroscopy assessment in a systemic sclerosis cohort: a two-centre study. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1092-1096.	0.9	132
16	Nailfold Videocapillaroscopic Features and Other Clinical Risk Factors for Digital Ulcers in Systemic Sclerosis: A Multicenter, Prospective Cohort Study. <i>Arthritis and Rheumatology</i> , 2016, 68, 2527-2539.	5.6	122
17	An EULAR study group pilot study on reliability of simple capillaroscopic definitions to describe capillary morphology in rheumatic diseases. <i>Rheumatology</i> , 2016, 55, 883-890.	1.9	121
18	Nailfold capillaroscopy for day-to-day clinical use: construction of a simple scoring modality as a clinical prognostic index for digital trophic lesions. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 180-183.	0.9	110

#	ARTICLE	IF	CITATIONS
19	Nailfold capillaroscopy in systemic sclerosis: Data from the EULAR scleroderma trials and research (EUSTAR) database. <i>Microvascular Research</i> , 2013, 89, 122-128.	2.5	101
20	State of the art on nailfold capillaroscopy: a reliable diagnostic tool and putative biomarker in rheumatology?. <i>Rheumatology</i> , 2013, 52, 1933-1940.	1.9	94
21	Malignancies in Patients with Anti-RNA Polymerase III Antibodies and Systemic Sclerosis: Analysis of the EULAR Scleroderma Trials and Research Cohort and Possible Recommendations for Screening. <i>Journal of Rheumatology</i> , 2017, 44, 639-647.	2.0	93
22	Timing of transition between capillaroscopic patterns in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2012, 64, 821-825.	6.7	92
23	Systemic sclerosis: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2019, 4, e000782.	3.8	91
24	Two-year Results of an Open Pilot Study of a 2-treatment Course with Rituximab in Patients with Early Systemic Sclerosis with Diffuse Skin Involvement. <i>Journal of Rheumatology</i> , 2013, 40, 52-57.	2.0	86
25	Nailfold capillaroscopy in systemic lupus erythematosus: A systematic review and critical appraisal. <i>Autoimmunity Reviews</i> , 2018, 17, 344-352.	5.8	84
26	Fast track algorithm: How to differentiate a "scleroderma pattern" from a "non-scleroderma pattern". <i>Autoimmunity Reviews</i> , 2019, 18, 102394.	5.8	79
27	Longterm Effects of Endothelin Receptor Antagonism on Microvascular Damage Evaluated by Nailfold Capillaroscopic Analysis in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2013, 40, 40-45.	2.0	77
28	Sequential nailfold videocapillaroscopy examinations have responsiveness to detect organ progression in systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 86-94.	3.4	71
29	Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 618-625.	0.9	71
30	Increase in circulating cells coexpressing M1 and M2 macrophage surface markers in patients with systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1842-1845.	0.9	70
31	Systemic lupus erythematosus: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2019, 4, e000793.	3.8	66
32	Effects of Longterm Treatment with Bosentan and Iloprost on Nailfold Absolute Capillary Number, Fingertip Blood Perfusion, and Clinical Status in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2016, 43, 2033-2041.	2.0	64
33	Correlations between angiogenic factors and capillaroscopic patterns in systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2013, 15, R55.	3.5	62
34	Vitamin D and Lung Outcomes in Elderly COVID-19 Patients. <i>Nutrients</i> , 2021, 13, 717.	4.1	61
35	Longterm Treatment with Endothelin Receptor Antagonist Bosentan and Iloprost Improves Fingertip Blood Perfusion in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2014, 41, 881-886.	2.0	60
36	Reliability of simple capillaroscopic definitions in describing capillary morphology in rheumatic diseases. <i>Rheumatology</i> , 2018, 57, 757-759.	1.9	60

#	ARTICLE	IF	CITATIONS
37	Functional disability and its predictors in systemic sclerosis: a study from the DeSSciper project within the EUSTAR group. <i>Rheumatology</i> , 2018, 57, 441-450.	1.9	60
38	Growth Differentiation Factor 15, a Marker of Lung Involvement in Systemic Sclerosis, Is Involved in Fibrosis Development but Is not Indispensable for Fibrosis Development. <i>Arthritis and Rheumatology</i> , 2014, 66, 418-427.	5.6	54
39	Nailfold Capillaroscopy and Clinical Applications in Systemic Sclerosis. <i>Microcirculation</i> , 2016, 23, 364-372.	1.8	50
40	Screening for pulmonary arterial hypertension in an unselected prospective systemic sclerosis cohort. <i>European Respiratory Journal</i> , 2017, 49, 1602275.	6.7	50
41	Dickkopf-1 (Dkk-1) serum levels in systemic sclerosis and rheumatoid arthritis patients: correlation with the Trabecular Bone Score (TBS). <i>Clinical Rheumatology</i> , 2018, 37, 3057-3062.	2.2	48
42	State of the art on nailfold capillaroscopy in dermatomyositis and polymyositis. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 432-444.	3.4	47
43	Quantitative Alterations of Capillary Diameter Have a Predictive Value for Development of the Capillaroscopic Systemic Sclerosis Pattern. <i>Journal of Rheumatology</i> , 2016, 43, 599-606.	2.0	45
44	Progression of Nailfold Microvascular Damage and Antinuclear Antibody Pattern in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2013, 40, 634-639.	2.0	44
45	Short-term follow-up of digital ulcers by laser speckle contrast analysis in systemic sclerosis patients. <i>Microvascular Research</i> , 2015, 101, 82-85.	2.5	44
46	Correlation between bone quality and microvascular damage in systemic sclerosis patients. <i>Rheumatology</i> , 2018, 57, 1548-1554.	1.9	44
47	Vitamin D deficiency and clinical correlations in systemic sclerosis patients: A retrospective analysis for possible future developments. <i>PLoS ONE</i> , 2017, 12, e0179062.	2.5	44
48	Relapsing polychondritis: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2018, 4, e000788.	3.8	43
49	Correlation between circulating fibrocytes and dermal thickness in limited cutaneous systemic sclerosis patients: a pilot study. <i>Rheumatology International</i> , 2019, 39, 1369-1376.	3.0	43
50	Detection of microvascular changes in systemic sclerosis and other rheumatic diseases. <i>Nature Reviews Rheumatology</i> , 2021, 17, 665-677.	8.0	42
51	Progression of patients with Raynaud's phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for Very Early Diagnosis of Systemic Sclerosis (VEDOSS). <i>Lancet Rheumatology</i> , The, 2021, 3, e834-e843.	3.9	42
52	Reliability of the quantitative assessment of peripheral blood perfusion by laser speckle contrast analysis in a systemic sclerosis cohort. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1263-1264.	0.9	40
53	Innovations in the Assessment of Primary and Secondary Raynaud's Phenomenon. <i>Frontiers in Pharmacology</i> , 2019, 10, 360.	3.5	40
54	Stabilization of Microcirculation in Patients with Early Systemic Sclerosis with Diffuse Skin Involvement following Rituximab Treatment: An Open-label Study. <i>Journal of Rheumatology</i> , 2016, 43, 995-996.	2.0	39

#	ARTICLE	IF	CITATIONS
55	Antiphospholipid syndrome: state of the art on clinical practice guidelines. RMD Open, 2018, 4, e000785.	3.8	38
56	Is laser speckle contrast analysis (LASCA) the new kid on the block in systemic sclerosis? A systematic literature review and pilot study to evaluate reliability of LASCA to measure peripheral blood perfusion in scleroderma patients. Autoimmunity Reviews, 2018, 17, 775-780.	5.8	38
57	Two years follow-up of an open-label pilot study of treatment with rituximab in patients with early diffuse cutaneous systemic sclerosis. Acta Clinica Belgica, 2018, 73, 119-125.	1.2	37
58	Nailfold Capillaroscopy Characteristics of Antisynthetase Syndrome and Possible Clinical Associations: Results of a Multicenter International Study. Journal of Rheumatology, 2019, 46, 279-284.	2.0	36
59	The Belgian Systemic Sclerosis Cohort: Correlations Between Disease Severity Scores, Cutaneous Subsets, and Autoantibody Profile. Journal of Rheumatology, 2012, 39, 2127-2133.	2.0	34
60	Automated assessment of absolute nailfold capillary number on videocapillaroscopic images: Proof of principle and validation in systemic sclerosis. Microcirculation, 2018, 25, e12447.	1.8	34
61	Sjögren's syndrome: state of the art on clinical practice guidelines. RMD Open, 2018, 4, e000789.	3.8	34
62	The clinical phenotype of systemic sclerosis patients with anti-PM/Scl antibodies: results from the EUSTAR cohort. Rheumatology, 2021, 60, 5028-5041.	1.9	34
63	An international Survey on non-invasive techniques to assess the microcirculation in patients with Raynaud's phenomenon (SUNSHINE survey). Rheumatology International, 2017, 37, 1879-1890.	3.0	33
64	Six-minute walk test in systemic sclerosis: A systematic review and meta-analysis. International Journal of Cardiology, 2016, 212, 265-273.	1.7	32
65	Intra-and inter-observer reliability of nailfold videocapillaroscopy – A possible outcome measure for systemic sclerosis-related microangiopathy. Microvascular Research, 2017, 112, 1-6.	2.5	31
66	Mixed connective tissue disease: state of the art on clinical practice guidelines. RMD Open, 2019, 4, e000783.	3.8	30
67	Evidences for a protective role of vitamin D in COVID-19. RMD Open, 2020, 6, e001454.	3.8	30
68	Capillaroscopy in Routine Diagnostics: Potentials and Limitations. Current Rheumatology Reviews, 2018, 14, 5-11.	0.8	29
69	Histopathological cutaneous alterations in systemic sclerosis: a clinicopathological study. Arthritis Research and Therapy, 2011, 13, R35.	3.5	28
70	Undifferentiated connective tissue disease: state of the art on clinical practice guidelines. RMD Open, 2019, 4, e000786.	3.8	28
71	Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group study. Rheumatology, 2020, 59, 1684-1694.	1.9	27
72	Progression of nailfold capillaroscopic patterns and correlation with organ involvement in systemic sclerosis: a 12 year study. Rheumatology, 2020, 59, 1051-1058.	1.9	27

#	ARTICLE	IF	CITATIONS
73	Ocular involvement in systemic sclerosis: A systematic literature review, it's not all scleroderma that meets the eye. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 119-125.	3.4	26
74	Value of systolic pulmonary arterial pressure as a prognostic factor of death in the systemic sclerosis EUSTAR population. <i>Rheumatology</i> , 2015, 54, 1262-1269.	1.9	25
75	Plasma endothelial microparticles reflect the extent of capillaroscopic alterations and correlate with the severity of skin involvement in systemic sclerosis. <i>Microvascular Research</i> , 2017, 110, 24-31.	2.5	25
76	Nailfold Videocapillaroscopy in Systemic Sclerosis-related Pulmonary Arterial Hypertension: A Systematic Literature Review. <i>Journal of Rheumatology</i> , 2020, 47, 888-895.	2.0	24
77	Early Diagnostic and Predictive Value of Capillaroscopy in Systemic Sclerosis. <i>Current Rheumatology Reviews</i> , 2014, 9, 249-253.	0.8	24
78	Quantitative outcome measures for systemic sclerosis-related Microangiopathy – Reliability of image acquisition in Nailfold Capillaroscopy. <i>Microvascular Research</i> , 2017, 113, 56-59.	2.5	23
79	Points to consider – Raynaud’s phenomenon in systemic sclerosis. <i>Rheumatology</i> , 2017, 56, v45-v48.	1.9	23
80	Advances in nailfold capillaroscopic analysis in systemic sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2018, 3, 122-131.	1.7	23
81	The emerging application of semi-quantitative and quantitative capillaroscopy in systemic sclerosis. <i>Microvascular Research</i> , 2018, 118, 113-120.	2.5	23
82	Ehlers-Danlos syndromes: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2018, 4, e000790.	3.8	23
83	Capillaroscopy as an Outcome Measure for Clinical Trials on the Peripheral Vasculopathy in SSc – Is It Useful?. <i>International Journal of Rheumatology</i> , 2010, 2010, 1-6.	1.6	22
84	Distinctive association of peripheral immune cell phenotypes with capillaroscopic microvascular patterns in systemic sclerosis. <i>Rheumatology</i> , 2019, 58, 2273-2283.	1.9	22
85	A comprehensive framework for navigating patient care in systemic sclerosis: A global response to the need for improving the practice of diagnostic and preventive strategies in SSc. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021, 35, 101707.	3.3	22
86	Nailfold capillaroscopic parameters and skin telangiectasia patterns in patients with systemic sclerosis. <i>Microvascular Research</i> , 2017, 111, 20-24.	2.5	21
87	Imbalanced serum levels of Ang1, Ang2 and VEGF in systemic sclerosis: Integrated effects on microvascular reactivity. <i>Microvascular Research</i> , 2019, 125, 103881.	2.5	21
88	IgG4-related diseases: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2019, 4, e000787.	3.8	21
89	Ocular microvascular damage in autoimmune rheumatic diseases: The pathophysiological role of the immune system. <i>Autoimmunity Reviews</i> , 2021, 20, 102796.	5.8	21
90	Epidemiology of interstitial lung diseases and their progressive-fibrosing behaviour in six European countries. <i>ERJ Open Research</i> , 2022, 8, 00597-2021.	2.6	21

#	ARTICLE	IF	CITATIONS
91	Effects of selexipag and its active metabolite in contrasting the profibrotic myofibroblast activity in cultured scleroderma skin fibroblasts. <i>Arthritis Research and Therapy</i> , 2018, 20, 77.	3.5	20
92	Are diffuse and limited juvenile systemic sclerosis different in clinical presentation? Clinical characteristics of a juvenile systemic sclerosis cohort. <i>Journal of Scleroderma and Related Disorders</i> , 2019, 4, 49-61.	1.7	20
93	Reporting items for capillaroscopy in clinical research on musculoskeletal diseases: a systematic review and international Delphi consensus. <i>Rheumatology</i> , 2021, 60, 1410-1418.	1.9	20
94	Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort. <i>Rheumatology</i> , 2022, 61, 4786-4796.	1.9	20
95	Macrocirculation versus microcirculation and digital ulcers in systemic sclerosis patients. <i>Rheumatology</i> , 2017, 56, 1834-1836.	1.9	19
96	Idiopathic inflammatory myopathies: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2019, 4, e000784.	3.8	19
97	Significance of nailfold videocapillaroscopy in patients with idiopathic inflammatory myopathies. <i>Rheumatology</i> , 2019, 58, 120-130.	1.9	19
98	Nailfold capillaroscopy—how many fingers should be examined to detect abnormality?. <i>Rheumatology</i> , 2019, 58, 284-288.	1.9	19
99	Immunopathophysiology and clinical impact of uveitis in inflammatory rheumatic diseases: An update. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13572.	3.4	19
100	Influence of Seasonal Vitamin D Changes on Clinical Manifestations of Rheumatoid Arthritis and Systemic Sclerosis. <i>Frontiers in Immunology</i> , 2021, 12, 683665.	4.8	19
101	The assessment of nailfold capillaries: comparison of dermoscopy and nailfold videocapillaroscopy. <i>Rheumatology</i> , 2018, 57, 1115-1116.	1.9	18
102	Nailfold capillaroscopy in rheumatology: ready for the daily use but with care in terminology. <i>Clinical Rheumatology</i> , 2019, 38, 2293-2297.	2.2	18
103	May capillaroscopy be a candidate tool in future algorithms for SSC-ILD: Are we looking for the holy grail? A systematic review. <i>Autoimmunity Reviews</i> , 2020, 19, 102619.	5.8	18
104	Methods for the morphological and functional evaluation of microvascular damage in systemic sclerosis. <i>Korean Journal of Internal Medicine</i> , 2015, 30, 1.	1.7	18
105	Imaging of connective tissue diseases: Beyond visceral organ imaging?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2016, 30, 670-687.	3.3	17
106	Reproducibility and Utility of the 6-minute Walk Test in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2018, 45, 1273-1280.	2.0	17
107	Pharmacological treatments for SSc-ILD: Systematic review and critical appraisal of the evidence. <i>Autoimmunity Reviews</i> , 2021, 20, 102978.	5.8	17
108	Immune system activation in polymyalgia rheumatica: Which balance between autoinflammation and autoimmunity? A systematic review. <i>Autoimmunity Reviews</i> , 2022, 21, 102995.	5.8	17

#	ARTICLE	IF	CITATIONS
109	The preliminary validation of laser Doppler flowmetry in systemic sclerosis in accordance with the OMERACT filter: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 321-328.	3.4	16
110	Epigenetics, pregnancy and autoimmune rheumatic diseases. <i>Autoimmunity Reviews</i> , 2020, 19, 102685.	5.8	16
111	Clinical spectrum time course in non-Asian patients positive for anti-MDA5 antibodies. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 274-283.	0.8	16
112	Brief Report: Smoking in Systemic Sclerosis: A Longitudinal European Scleroderma Trials and Research Group Study. <i>Arthritis and Rheumatology</i> , 2018, 70, 1829-1834.	5.6	15
113	Specific anti-nuclear antibodies in systemic sclerosis patients with and without skin involvement: an extended methodological approach. <i>Rheumatology</i> , 2011, 50, 1302-1309.	1.9	14
114	Evaluating microangiopathy in systemic sclerosis: what have we learnt and what is left to discover?. Expert Review of <i>Clinical Immunology</i> , 2011, 7, 395-397.	3.0	14
115	Incidence and risk factors for gangrene in patients with systemic sclerosis from the EUSTAR cohort. <i>Rheumatology</i> , 2020, 59, 2016-2023.	1.9	14
116	Anticentromere Antibody Levels and Isotypes and the Development of Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2021, 73, 2338-2347.	5.6	14
117	CTLA4-Ig treatment induces M1 to M2 shift in cultured monocyte-derived macrophages from healthy subjects and rheumatoid arthritis patients. <i>Arthritis Research and Therapy</i> , 2021, 23, 306.	3.5	14
118	A comparison between nailfold capillaroscopy patterns in adulthood in juvenile and adult-onset systemic sclerosis: A EUSTAR exploratory study. <i>Microvascular Research</i> , 2015, 102, 19-24.	2.5	13
119	Progression of Organ Involvement in Systemic Sclerosis Patients with Persistent "Late" Nailfold Capillaroscopic Pattern of Microangiopathy: A Prospective Study. <i>Journal of Rheumatology</i> , 2017, 44, 1941-1942.	2.0	13
120	Might Nailfold Capillaroscopy Be a "Proxy" for Lung Involvement in Connective Tissue Diseases?. <i>Journal of Rheumatology</i> , 2019, 46, 1061-1063.	2.0	13
121	Longitudinal Assessment of Patient-reported Outcome Measures in Systemic Sclerosis Patients with Gastroesophageal Reflux Disease " Scleroderma Clinical Trials Consortium. <i>Journal of Rheumatology</i> , 2019, 46, 78-84.	2.0	13
122	Underdetection of Interstitial Lung Disease in Juvenile Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2022, 74, 364-370.	3.4	13
123	Differences Sustained Between Diffuse and Limited Forms of Juvenile Systemic Sclerosis in an Expanded International Cohort. <i>Arthritis Care and Research</i> , 2022, 74, 1575-1584.	3.4	13
124	The added value of a European Reference Network on rare and complex connective tissue and musculoskeletal diseases: insights after the first 5 years of the ERN ReCONNET. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 3-11.	0.8	12
125	Nutritional Status and Bone Microarchitecture in a Cohort of Systemic Sclerosis Patients. <i>Nutrients</i> , 2020, 12, 1632.	4.1	11
126	A randomised, open-label trial to assess the optimal treatment strategy in early diffuse cutaneous systemic sclerosis: the UPSIDE study protocol. <i>BMJ Open</i> , 2021, 11, e044483.	1.9	11



#	ARTICLE	IF	CITATIONS
127	Nailfold capillary abnormalities in childhood-onset systemic lupus erythematosus: a cross-sectional study compared with healthy controls. <i>Lupus</i> , 2021, 30, 818-827.	1.6	11
128	Antiphospholipid antibodies and anticoagulant therapy: capillaroscopic findings. <i>Arthritis Research and Therapy</i> , 2021, 23, 175.	3.5	11
129	Dyspnoea and cough in patients with systemic sclerosis-associated interstitial lung disease in the SENSICIS trial. <i>Rheumatology</i> , 2022, 61, 4397-4408.	1.9	11
130	Understanding immune effects of oestrogens to explain the reduced morbidity and mortality in female versus male COVID-19 patients. Comparisons with autoimmunity and vaccination. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 383-386.	0.8	11
131	Detailed videocapillaroscopic microvascular changes detectable in adult COVID-19 survivors. <i>Microvascular Research</i> , 2022, 142, 104361.	2.5	11
132	Training in Capillaroscopy: A Growing Interest: Figure 1.. <i>Journal of Rheumatology</i> , 2012, 39, 1113-1116.	2.0	10
133	Effects of Macitentan and Its Active Metabolite on Cultured Human Systemic Sclerosis and Control Skin Fibroblasts. <i>Journal of Rheumatology</i> , 2015, 42, 456-463.	2.0	10
134	Primary Raynaud's phenomenon and nailfold videocapillaroscopy: age-related changes in capillary morphology. <i>Clinical Rheumatology</i> , 2017, 36, 1637-1642.	2.2	10
135	Effects of CTLA4-Ig treatment on circulating fibrocytes and skin fibroblasts from the same systemic sclerosis patients: an in vitro assay. <i>Arthritis Research and Therapy</i> , 2018, 20, 157.	3.5	10
136	Identifying unmet needs in SSc-ILD by semi-qualitative in-depth interviews. <i>Rheumatology</i> , 2021, 60, 5601-5609.	1.9	10
137	Nintedanib downregulates the transition of cultured systemic sclerosis fibrocytes into myofibroblasts and their pro-fibrotic activity. <i>Arthritis Research and Therapy</i> , 2021, 23, 205.	3.5	10
138	Content of non-pharmacological care for systemic sclerosis and educational needs of European health professionals: a EUSHNet survey. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S153-9.	0.8	10
139	Raynaud's syndrome in children: systematic review and development of recommendations for assessment and monitoring. <i>Clinical and Experimental Rheumatology</i> , 2016, 34 Suppl 100, 200-206.	0.8	10
140	Nailfold capillaroscopy in SSc: innocent bystander or promising biomarker for novel severe organ involvement/progression?. <i>Rheumatology</i> , 2022, 61, 4384-4396.	1.9	10
141	Capillaroscopic analysis of the microvascular status in mixed versus undifferentiated connective tissue disease. <i>Microvascular Research</i> , 2022, 142, 104367.	2.5	10
142	Prevalence and incidence of pulmonary arterial hypertension: 10-year follow-up of an unselected systemic sclerosis cohort. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, 196-202.	1.7	9
143	The role of nailfold videocapillaroscopy in patients with systemic sclerosis. <i>Immunological Medicine</i> , 2018, 41, 113-119.	2.6	9
144	Coexistence of systemic and localized scleroderma: a systematic literature review and observational cohort study. <i>Rheumatology</i> , 2020, 59, 2725-2733.	1.9	9

#	ARTICLE	IF	CITATIONS
145	Standardised interpretation of capillaroscopy in autoimmune idiopathic inflammatory myopathies: A structured review on behalf of the EULAR study group on microcirculation in Rheumatic Diseases. <i>Autoimmunity Reviews</i> , 2022, 21, 103087.	5.8	9
146	Nailfold Capillaroscopy. , 2012, , 331-346.		8
147	Nailfold capillary abnormalities in erectile dysfunction of systemic sclerosis: a EUSTAR group analysis. <i>Rheumatology</i> , 2014, 53, 639-643.	1.9	8
148	Lower urinary tract symptoms in systemic sclerosis: a detailed investigation. <i>Rheumatology</i> , 2020, 59, 1315-1324.	1.9	8
149	Evaluation of the primary biliary cholangitis-related serologic profile in a large cohort of Belgian systemic sclerosis patients. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 416-423.	2.3	8
150	Incidence, prevalence and long-term progression of Goh algorithm rated interstitial lung disease in systemic sclerosis in two independent cohorts in flanders: A retrospective cohort study. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 969-976.	3.4	8
151	Specific Antinuclear Antibody Level Changes after B Cell Depletion Therapy in Systemic Sclerosis Are Associated with Improvement of Skin Thickening. <i>Journal of Rheumatology</i> , 2016, 43, 247-249.	2.0	7
152	Metabolic Profile and Bone Status in Post-Menopausal Women with Rheumatoid Arthritis: A Monocentric Retrospective Survey. <i>Nutrients</i> , 2021, 13, 3168.	4.1	7
153	Anti-RuvBL1/2 autoantibodies in patients with systemic sclerosis or idiopathic inflammatory myopathy and a nuclear speckled pattern. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 742-744.	0.9	7
154	Clinical practice guidelines adherence, knowledge and awareness in rare and complex connective tissue diseases across Europe: results from the first ERN ReCONNET survey. <i>RMD Open</i> , 2020, 6, e001344.	3.8	6
155	Durometry in SSc: The hard facts. A systematic literature review and additional pilot study. <i>Rheumatology</i> , 2021, 60, 2099-2108.	1.9	6
156	High frequency ultrasonography: reliable tool to measure skin fibrosis in SSC? A systematic literature review and additional pilot study. <i>Rheumatology</i> , 2021, 61, 42-52.	1.9	6
157	Engineered glove to evaluate hand disability in rheumatoid arthritis: A pilot-study. <i>Joint Bone Spine</i> , 2022, 89, 105272.	1.6	6
158	Body composition and bone status in relation to microvascular damage in systemic sclerosis patients. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 255-264.	3.3	6
159	Nailfold capillaroscopy in Sjögren's syndrome: a systematic literature review and standardised interpretation. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 126, 150-157.	0.8	6
160	Apremilast interferes with the TGFβ1-induced transition of human skin fibroblasts into profibrotic myofibroblasts: in vitro study. <i>Rheumatology</i> , 2020, 59, 3927-3938.	1.9	5
161	Representativeness of systemic sclerosis patients in interventional randomized trials: an analysis of the EUSTAR database. <i>Rheumatology</i> , 2022, 61, 743-755.	1.9	5
162	The burden of systemic sclerosis in Switzerland – the Swiss systemic sclerosis EUSTAR cohort. <i>Swiss Medical Weekly</i> , 2021, 151, w20528.	1.6	5

#	ARTICLE	IF	CITATIONS
163	Peripheral blood perfusion in patients with systemic lupus erythematosus and in primary Raynaud's phenomenon. <i>European Journal of Rheumatology</i> , 2021, 8, 7-11.	0.6	5
164	Disease activity indices in systemic sclerosis: a systematic literature review. <i>Clinical and Experimental Rheumatology</i> , 2016, 34 Suppl 100, 186-192.	0.8	5
165	Results from an American pilot survey among Scleroderma Clinical Trials Consortium members on capillaroscopy use and how to best implement nailfold capillaroscopy training. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 119, 151.	0.8	5
166	Long-term follow-up of nailfold videocapillaroscopic microvascular parameters in mixed connective tissue disease versus systemic sclerosis patients: a retrospective cohort study. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 119, 102-107.	0.8	5
167	Predictive value of laser speckle contrast analysis in systemic sclerosis. A systematic review and pilot study. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13672.	3.4	4
168	Is There a Link Between Nailfold Videocapillaroscopy and Pulmonary Function Tests in Systemic Sclerosis Patients?. <i>Journal of Clinical Rheumatology</i> , 2022, 28, 26-32.	0.9	4
169	Six-minute walk test in or out in evaluation of systemic sclerosis patients?. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 106, 122-129.	0.8	4
170	Pitfalls in the detection of myositis specific antibodies by lineblot in clinically suspected idiopathic inflammatory myopathy. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 212-219.	0.8	4
171	Health-related quality of life in patients with mixed connective tissue disease: a comparison with matched systemic sclerosis patients. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 66-70.	0.8	4
172	SAT0296...FAST TRACK ALGORITHM: HOW TO DIFFERENTIATE A SCLERODERMA PATTERN FROM A NON-SCLERODERMA PATTERN. , 2019, , .		3
173	Nailfold capillary scleroderma pattern may be associated with disease damage in childhood-onset systemic lupus erythematosus: important lessons from longitudinal follow-up. <i>Lupus Science and Medicine</i> , 2022, 9, e000572.	2.7	3
174	Full longitudinal nailfold videocapillaroscopy analysis of microvascular changes during normal pregnancy. <i>Microvascular Research</i> , 2022, , 104343.	2.5	3
175	Integration of capillary microscopy and dermoscopy into the rheumatology fellow curriculum. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 850-852.	0.8	3
176	Capillaroscopy in childhood-onset systemic lupus erythematosus: a first systematic review. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 350-354.	0.8	3
177	Sjögren's syndrome and other rare and complex connective tissue diseases: an intriguing liaison. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 103-112.	0.8	3
178	Is there a role for nailfold videocapillaroscopy in interstitial lung disease?. <i>Rheumatology</i> , 2022, , .	1.9	3
179	Laser speckle contrast analysis is a reliable measure of digital blood perfusion in Black Africans with systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 119-123.	0.8	3
180	Off-label use of mycophenolate mofetil in the treatment of rare and complex rheumatic connective tissue diseases. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 32-39.	0.8	3

#	ARTICLE	IF	CITATIONS
181	Late Skin Fibrosis in Systemic Sclerosis: A Study from the EUSTAR Cohort. <i>Rheumatology</i> , 0, , .	1.9	3
182	Rapidly growing gastric metastasis of Merkel cell carcinoma, an unusual cause of melena. <i>Acta Clinica Belgica</i> , 2016, 71, 263-266.	1.2	2
183	FRI0501â€¦EVALUATION OF BONE QUALITY BY TRABECULAR BONE SCORE (TBS) IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS. , 2019, , .		2
184	Capillaroscopy. , 2014, , 93-99.		2
185	Nailfold Capillaroscopy. , 2015, , 187-197.		2
186	A prospective, longitudinal study evaluating the baseline six-minute walk test as an individual reference value in systemic sclerosis patients. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 113, 95-101.	0.8	2
187	The impact of transducer frequency in ultrasound evaluation of subclinical skin involvement in limited cutaneous systemic sclerosis patients. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 119, 147-148.	0.8	2
188	Consensus-based evaluation of dermatoscopy versus nailfold videocapillaroscopy in Raynaud's phenomenon linking USA and Europe: a European League against Rheumatism study group on microcirculation in rheumatic diseases project. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 125, 132-136.	0.8	2
189	Rarities in rare: illuminating the microvascular and dermal status in juvenile localised scleroderma. A case series. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 12-18.	0.8	2
190	Response to: Comparison of laser Doppler imaging, fingertip lacticy test, and nailfold capillaroscopy for assessment of digital microcirculation in systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2010, 13, 301.	3.5	1
191	FRI0345â€¦CAPILLAROSCOPY IN SYSTEMIC SCLEROSIS RELATED PULMONARY ARTERIAL HYPERTENSION. , 2019, , .		1
192	Capillary Microscopy. , 2019, , 63-78.		1
193	ADVANCES IN THERAPIES FOR SYSTEMIC SCLEROSIS. , 2015, , 165-198.		1
194	Assessment of sensitivity to change of the European Scleroderma Study Group activity index. <i>Clinical and Experimental Rheumatology</i> , 2016, 34 Suppl 100, 148-151.	0.8	1
195	Advanced microvascular damage associated with occurrence of sarcopenia in systemic sclerosis patients: results from a retrospective cohort study. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 125, 65-72.	0.8	1
196	Reliable detection of subtypes of nailfold capillary haemorrhages in childhood-onset systemic lupus erythematosus. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 1126-1131.	0.8	1
197	A4.8â€¦GDF15, A Marker of Lung Involvement in Systemic Sclerosis, is Involved in Altered Cytokine Secretion by Fibroblasts, but does not Impair Fibrosis Development. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A26.2-A26.	0.9	0
198	Automated indirect immunofluorescence antinuclear antibody analysis is a standardized alternative for visual microscope interpretation. <i>Clinical Chemistry and Laboratory Medicine</i> , 2014, 52, .	2.3	0

#	ARTICLE	IF	CITATIONS
199	051.â€fQUANTITATIVE OUTCOME MEASURES FOR SYSTEMIC SCLEROSISâ€“RELATED MICROANGIOPATHY: RELIABILITY OF IMAGE ACQUISITION IN NAILFOLD CAPILLAROSCOPY. Rheumatology, 2017, 56, .	1.9	0
200	159â€fDermoscopy versus videocapillaroscopy in the assessment of nailfold capillaroscopy images in patients with systemic sclerosis and healthy controls. Rheumatology, 2018, 57, .	1.9	0
201	FRI0341â€f...LOWER URINARY TRACT SYMPTOMS PREVALENCE IN SYSTEMIC SCLEROSIS PATIENTS: RESULTS FROM A COMPREHENSIVE ANALYSIS. , 2019, , .		0
202	SP0024â€f...STANDARDISATION OF NORMAL VERSUS ABNORMAL AND PATHOLOGICAL CAPILLAROSCOPIC IMAGES. , 2019, , .		0
203	SAT0252â€f...AN EVALUATION OF THREE DIFFERENT METHODS TO EVALUATE SKIN IMPAIRMENT IN SYSTEMIC SCLEROSIS PATIENTS. , 2019, , .		0
204	AB0682â€f...CIRCULATING FIBROCYTES IN LIMITED CUTANEOUS SYSTEMIC SCLEROSIS PATIENTS: CORRELATION WITH DERMAL THICKNESS. , 2019, , .		0
205	SAT0293â€f...SPECIFIC ALTERATIONS OF NAILFOLD CAPILLARIES MIGHT ANTICIPATE THE APPEARANCE OF THE EARLY CAPILLAROSCOPIC SCLERODERMA-PATTERN IN SYSTEMIC SCLEROSIS PATIENTS. , 2019, , .		0
206	THU0348â€f...IDENTIFICATION OF CIRCULATING CELLS WITH AN HYBRID M1/M2 MACROPHAGE PHENOTYPE IN SYSTEMIC SCLEROSIS PATIENTS AND CORRELATIONS WITH SELECTED CLINICAL ASPECTS. , 2019, , .		0
207	AB1133â€f...ALITOMATED ASSESSMENT (AUTOCAP) OF NAILFOLD CAPILLARY NUMBER VERSUS MANUAL COUNTING IN SYSTEMIC SCLEROSIS PATIENTS WITH DIFFERENT CAPILLAROSCOPIC PATTERNS. , 2019, , .		0
208	AB1143â€f...SUBCLINICAL MICROVASCULAR INVOLVEMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS. , 2019, , .		0
209	THU0347â€f...TESTING THE IN VITRO EFFECTS OF NINTEDANIB ON CIRCULATING FIBROCYTES AND RESIDENT SKIN FIBROBLASTS FROM THE SAME SYSTEMIC SCLEROSIS PATIENTS: PRELIMINARY RESULTS. , 2019, , .		0
210	AB0654â€f...NAILFOLD MICROVASCULAR CHANGES IN MIXED CONNECTIVE TISSUE DISEASE: DIFFERENCES WITH SYSTEMIC SCLEROSIS. , 2019, , .		0
211	THU0053â€f...APREMILAST INHIBITS THE TGFâ€™1 MEDIATED TRANSITION OF CULTURED HUMAN SKIN FIBROBLASTS INTO PROFIBROTIC MYOFIBROBLASTS: IN VITRO STUDY. , 2019, , .		0
212	FRI0607â€f...IDENTIFICATION OF UNMET NEEDS RELATED TO RARE AND COMPLEX CONNECTIVE TISSUE AND MUSCULOSKELETAL DISEASES (RCTDS) ACROSS EU: THE EXPERIENCE OF THE ERN RECONNET. , 2019, , .		0
213	Comment on: Lower urinary tract symptoms in systemic sclerosis patients: a detailed investigation: reply. Rheumatology, 2020, 59, 1456-1457.	1.9	0
214	Peripheral ischaemic retinopathy and neovascularisation in a patient with subacute streptococcus mitis-induced bacterial endocarditis. GMS Ophthalmology Cases, 2017, 7, Doc25.	0.1	0
215	Factors influencing the occupational trajectory of patients with systemic sclerosis: a qualitative study. Clinical and Experimental Rheumatology, 2015, 33, S26-30.	0.8	0
216	Development of eosinophilic fasciitis during treatment with certolizumab pegol for ankylosing spondylitis. Clinical and Experimental Rheumatology, 2020, 38, 799.	0.8	0

#	ARTICLE	IF	CITATIONS
217	Laser speckle contrast analysis in rheumatoid arthritis: a pilot study. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.8	0
218	Laser speckle contrast analysis is a reliable measure of digital blood perfusion in Black Africans with systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 131, 119-123.	0.8	0
219	Laser speckle contrast analysis in rheumatoid arthritis: a pilot study. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 129-134.	0.8	0
220	Rarities in rare: illuminating the microvascular and dermal status in juvenile localised scleroderma. A case series.. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.8	0
221	Clinical spectrum time course in non-Asian patients positive for anti-MDA5 antibodies.. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 274-283.	0.8	0
222	Off-label use of mycophenolate mofetil in the treatment of rare and complex rheumatic connective tissue diseases.. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.8	0
223	The added value of a European Reference Network on rare and complex connective tissue and musculoskeletal diseases: insights after the first 5 years of the ERN ReCONNET.. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.8	0
224	Sjögren's syndrome and other rare and complex connective tissue diseases: an intriguing liaison.. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.8	0